Munich:BSLN

Basilea awarded additional CARB-X funding of USD6million to support the clinical development of antibiotic BAL2420

Funding is awarded following successful completion of IND-enabling studies and clinical study authorizationĀ USD 6 million in additional funding to support…

8 hours ago

Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a…

9 months ago